VALBIOTIS

VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.

TOTUM-070

VALBIOTIS presents the first market data on untreated LDL-hypercholesterolemia for TOTUM-070, and announces the initiation of the Phase II clinical study HEART.

Learn more

EASD

VALBIOTIS selected to present 3 studies on TOTUM-63 by the European Association for the Study of Diabetes (EASD).

Learn more

TOTUM-63

First Patient First Visit in the international Phase II/III REVERSE-IT clinical study on TOTUM-63 to reduce Type 2 Diabetes risk factors.

Learn more

VALBIOTIS

VALBIOTIS announces a global strategic partnership with NESTLÉ HEALTH SCIENCE for the development and commercialization of TOTUM-63

Learn more
S c r o l l

Products

.01

TOTUM-63

Prediabetes, risk condition for Type 2 Diabetes
> Clinical Phase II positive
> Clinical Phase II/III pending

Learn more

.02

TOTUM-070

Mild to moderate hypercholesterolemia, risk factor for cardiovascular diseases
> Clinical Phase II initiated

Learn more

.03

TOTUM-448

Non-alcoholic hepatic steatosis, risk condition for NASH
> Clinical Phase II pending

Learn more

.04

TOTUM-854

Elevated blood pressure, a risk factor for cardiovascular diseases
> Clinical Phase II pending

Learn more

Key figures

Patent families filed

4
All exploitation rights obtained

Employees

> 35
75% in R&D

Listed on the Stock Exchange

2017
Euronext Growth

Our last posts

03.11.2020

Annual Meeting of the European Association for the Study of Diabetes (EASD)

En savoir plus
12.06.2020

80th scientific sessions of the American Diabetes Association

En savoir plus
11.02.2020

Investor meetings – Portzamparc

En savoir plus
28.01.2020

Biomed Event

En savoir plus
Voir tous

VALBIOTIS© listed on the Stock Exchange

Follow us!

See more